Highlights MindBio Therapeutics Corp.

Equities

MBIO

CA60256C1086

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-07-11 am EDT			5-day change	1st Jan Change
0.04 ^CAD	+33.33%		+33.33%	+60.00%

Jun. 20	MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001	CI
Jun. 12	Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001	Jun. 20	CI
Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial	Jun. 12	CI
MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 13	CI
Mindbio Therapeutics Corp. Announces Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3	May. 02	CI
MindBio Therapeutics Corp. Announces the Regulatory Approval of A Series of Clinical Trials in Women's Health Using MB22001	Apr. 30	CI
MindBio Beginning Landmark Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	Mar. 20	MT
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	Mar. 20	CI
MindBio Therapeutics Receives Final Approval to Conduct Phase 2B Trial Microdosing Mb22001 in Patients With MDD	Mar. 04	MT
Mindbio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder	Mar. 04	CI
MindBio Therapeutics Corp. Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial	Feb. 26	CI
MindBio Therapeutics Corp. Completes World First Take Home Phase 2a Microdosing Depression Trial	Feb. 14	CI
MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder	Jan. 30	CI
MindBio Therapeutics Corp. CEO Provides End of Year Video Update on Phase 2 Clinical Trials	Dec. 20	CI
MindBio Therapeutics Corp. Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer	23-10-31	CI
MindBio Therapeutics Corp. Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial in Advanced Stage Cancer Patients	23-10-28	CI
Mindbio Therapeutics Corp. Provides Video Update on Phase 2a Depression Trial Using MB22001	23-10-24	CI
MindBio Therapeutics Corp. Announces Tenth Patient with Depression Starts Dosing MB22001 in Take Home Microdosing Trials	23-10-05	CI
MindBio Therapeutics Corp. Begins Selection of Participants for its Phase 2 Randomized Double-Blind and Placebo Controlled Clinical Trial in Advanced Stage Cancer Patients Using Microdoses of Lylergic Acid Diethylamide and Meaning Centred Psychotherapy	23-10-04	CI
MindBio Therapeutics Corp. Announces Major Genetic Discovery in Microdosing Research	23-09-05	CI
MindBio Therapeutics Corp. Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression	23-08-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MindBio Therapeutics Corp.

Equities

MBIO

CA60256C1086

Highlights

Filters